At the protein level, osimertinib at 100–500 nM range decreased TRPM2 protein levels in three EGFRm NSCLC cell lines, but did not do so even at 500 nM in 3 NSCLC cell lines with WT EGFR (Figure 1C), suggesting a mutation‐selective effect. This evidence concerns the gene TRPM2 and non-small cell lung carcinoma.